Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jadohealth.2021.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of Cannabis Product Characteristics and Pricing on Dark Web Markets.
J Psychoactive Drugs
January 2025
Global Health Policy and Data Institute, San Diego, CA, USA.
Growing cannabis use has made it the most widely cultivated and trafficked illicit drug globally according to the World Health Organization, with 147 million people consuming cannabis-derived products (CDPs) in various product forms and constituency. Despite restrictions in certain countries, unregulated access can still be found on the dark web which specializes in trafficking of illicit goods. The objective was to systematically collect data from multiple marketplaces to identify types of cannabis products offered for sale.
View Article and Find Full Text PDFSelenium: 48-year journey of global clinical trials.
Mol Cell Biochem
January 2025
Department of Urology, Guizhou Provincial People's Hospital, Guiyang, 550002, China.
Selenium, an essential trace mineral for health, has seen a rise in clinical trials over the past nearly 5 decades. Our aim here is to provide a comprehensive and concise overview of selenium clinical trials from 1976 to 2023. Overall, the evolution of selenium clinical trials over 48 years has advanced through phases of emergence, prosperity, and either stability or transition.
View Article and Find Full Text PDFStudy protocol for a Prospective Observational study of Safety Threats and Adverse events in Trauma (PrO-STAT): a pilot study at a level-1 trauma centre in Canada.
BMJ Open
January 2025
Department of Emergency Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
Introduction: Traumatic injuries are a significant public health concern globally, resulting in substantial mortality, hospitalisation and healthcare burden. Despite the establishment of specialised trauma centres, there remains considerable variability in trauma-care practices and outcomes, particularly in the initial phase of trauma resuscitation in the trauma bay. This stage is prone to preventable errors leading to adverse events (AEs) that can impact patient outcomes.
View Article and Find Full Text PDFSynergy of the flow behaviour and disperse phase of polysaccharide nanoparticles derived from Corchorus olitorius in enhancing oil recovery at an offshore operation.
Int J Biol Macromol
January 2025
Department of Chemical Engineering, School of Engineering and Digital Science, Nazarbayev University, Astana 010000, Kazakhstan.
The escalating global energy demand necessitates enhanced oil recovery methods, particularly offshore. Biological nanotechnology offers sustainable, environment-friendly, and cost-effective alternatives to synthetic chemicals. This study explored the synthesis of polysaccharide-based nanoparticles (PNPs) from Corchorus olitorius leaves using a weak acid-assisted ultrasonic method and their application as nanocomposites for oil recovery.
View Article and Find Full Text PDFA Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
J Thorac Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa-Nishi-machi, Kanagawa-ku, Yokohama 221-0855, Japan.
Introduction: Osimertinib is the first-line treatment for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations and favorable performance status (PS). Despite increasing clinical data on osimertinib, evidence in patients with an impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor PS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!